Profile data is unavailable for this security.
About the company
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
- Revenue in USD (TTM)101.90m
- Net income in USD-6.24m
- Incorporated2001
- Employees141.00
- LocationSanara Medtech Inc1200 Summit Avenue, Suite 414FORT WORTH 76102United StatesUSA
- Phone+1 (817) 529-2300
- Websitehttps://sanaramedtech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 90.98m | 71.00 | -- | -- | -- | 2.95 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
| Biostem Technologies Inc | 235.17m | 20.20m | 97.34m | 67.00 | 6.43 | 1.94 | 4.76 | 0.4139 | 0.9019 | 0.9019 | 11.60 | 2.98 | 2.82 | 2.61 | 4.65 | -- | 24.25 | -- | 55.07 | -- | 97.33 | -- | 8.59 | -- | 4.09 | -- | 0.0566 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
| Alpha Cognition Inc | 7.43m | -19.47m | 106.10m | 52.00 | -- | 2.34 | -- | 14.29 | -1.37 | -1.37 | 0.5002 | 2.09 | 0.2894 | -- | 5.22 | 142,830.80 | -75.87 | -119.10 | -93.86 | -159.05 | 73.09 | -- | -262.18 | -- | 6.03 | -7.91 | 0.00 | -- | -- | -- | -6.34 | -- | -- | -- |
| Fortress Biotech Inc | 62.30m | -5.34m | 112.05m | 101.00 | -- | 2.00 | -- | 1.80 | -0.293 | -0.293 | 2.16 | 1.80 | 0.4039 | 1.50 | 4.35 | 616,861.40 | -34.90 | -54.95 | -51.59 | -102.13 | 71.56 | 62.39 | -86.41 | -227.71 | 1.97 | -10.63 | 0.4503 | -- | -31.76 | 9.50 | 18.61 | -- | 25.88 | -- |
| Whitehawk Therapeutics Inc | 14.38m | -15.62m | 134.32m | 22.00 | 20.98 | 0.8546 | -- | 9.34 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 152.00m | 1.00 | -- | 0.8486 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.07m | -196.04m | 157.39m | 228.00 | -- | -- | -- | 1.08 | -16.60 | -16.60 | 13.36 | -16.00 | 1.07 | 1.36 | 5.13 | 640,644.80 | -143.71 | -55.11 | -442.98 | -78.19 | 95.93 | 96.83 | -134.21 | -87.65 | 1.08 | -2.11 | 47.44 | -- | 0.5715 | 6.21 | -156.52 | -- | -- | -- |
| Sanara Medtech Inc | 101.90m | -6.24m | 168.97m | 141.00 | -- | 27.47 | -- | 1.66 | -0.7292 | -4.34 | 11.86 | 0.6885 | 1.28 | 2.47 | 8.78 | 722,724.30 | -8.03 | -15.12 | -10.00 | -18.64 | 92.25 | 88.92 | -6.29 | -14.70 | 1.60 | 0.3039 | 0.8801 | -- | 33.36 | 49.09 | -124.59 | -- | -33.05 | -- |
| BGM Group Ltd | 26.85m | -2.72m | 178.70m | 323.00 | -- | 0.5937 | -- | 6.66 | -0.2816 | -0.2816 | 1.38 | 1.85 | 0.2087 | 3.21 | 8.60 | 83,116.91 | -2.08 | -0.0792 | -2.36 | -0.1065 | 19.41 | 10.38 | -9.95 | -0.0921 | 1.45 | -0.3408 | 0.0087 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Tonix Pharmaceuticals Holding Corp | 10.30m | -99.22m | 193.70m | 81.00 | -- | 0.666 | -- | 18.81 | -20.11 | -20.11 | 1.69 | 22.73 | 0.0593 | 0.9665 | 2.75 | 127,148.10 | -57.12 | -61.84 | -63.76 | -68.67 | 34.31 | -- | -963.38 | -2,797.35 | 9.62 | -- | 0.00 | -- | 29.94 | -- | -11.47 | -- | 47.82 | -- |
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Coherus Oncology Inc | 83.57m | -187.47m | 240.65m | 161.00 | -- | 2.13 | -- | 2.88 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Sanara Medtech Inc's reporting currency: US Dollar USD
17.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Robert W. Baird & Co., Inc. (Private Banking)as of 31 Dec 2025 | 760.29k | 8.51% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 169.74k | 1.90% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 156.79k | 1.76% |
| Stonebridge Wealth Management LLC (Illinois)as of 31 Dec 2025 | 134.93k | 1.51% |
| Geode Capital Management LLCas of 31 Dec 2025 | 79.05k | 0.89% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 62.29k | 0.70% |
| Squarepoint OPS LLCas of 31 Dec 2025 | 48.95k | 0.55% |
| Marshall Wace LLPas of 31 Dec 2025 | 48.61k | 0.54% |
| RBC Capital Markets LLC (Investment Management)as of 30 Sep 2025 | 44.66k | 0.50% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 37.60k | 0.42% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
